CJC-1295 Research Guide

Full name: CJC-1295 (Modified GRF 1-29)

A synthetic GHRH analog with 4 amino acid substitutions for stability. Often combined with DAC for extended half-life or used without DAC for pulsatile release.

How CJC-1295 Works

Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release.

Dosing Protocol

• Typical dose: 100-300 mcg
• Frequency: 1-3x daily (no-DAC)
• Duration: 8-16 weeks
• Route: Subcutaneous injection

Reported Benefits

• Increased GH production
• Improved body composition
• Enhanced recovery
• Better sleep quality
• Anti-aging effects
• Fat loss

Potential Side Effects

• Flushing
• Headache
• Water retention
• Tingling/numbness
• Increased hunger

Research Citations

1. CJC-1295 effects on GH secretion in healthy adults (2020) - Increased mean GH levels by 200-1000% and IGF-1 by 50-70% sustained over 6-14 days after single injection.
2. Pulsatile vs sustained GH release with GHRH analogs (2019) - Non-DAC CJC-1295 preserved physiological GH pulsatility while achieving 2-10x baseline elevation.

Related Growth Hormone Compounds

• Ipamorelin - Full Profile
• MK-677 (Ibutamoren) - Full Profile
• Sermorelin - Full Profile
• Tesamorelin - Full Profile
• GHRP-2 - Full Profile
• GHRP-6 - Full Profile

View full CJC-1295 profile with 3D molecule viewer →